Introduction: Obesity is frequently a comorbidity of type 2 diabetes. Even modest weight loss can significantly improve glucose homeostasis and lessen cardiometabolic risk factors in patients with type 2 diabetes, but life-style-based weight loss strategies are not long-term effective. There is an increasing need to consider pharma-cological approaches to assist weight loss in the so called diabesity syndrome. Aim of this review is to analyze the weight-loss effect of non-insulin glucose lowering drugs in patients with type 2 diabetes. Material and methods: A systematic analysis of the literature on the effect of non-insulin glucose lowering drugs on weight loss in patients with type 2 diabetes was performed. For each class of drugs, the following parameters were analyzed: kilograms lost on average, effect on body mass index and body composition. Results: Our results suggested that anti-diabetic drugs can be stratified into 3 groups based on their efficacy in weight loss: metformin, acarbose, empagliflozin and exenatide resulted in a in a mild weight loss (less than 3.2% of initial weight); canagliflozin, ertugliflozin, dapagliflozin and dulaglutide induces a moderate weight loss (between 3.2% and 5%); liraglutide, semaglutide and tirzepatide resulted in a strong weight loss (greater than 5%). Conclusions: This study shows that new anti-diabetic drugs, particularly GLP1-RA and Tirzepatide, are the most effective in inducing weight loss in patients with type 2 diabetes. Interestingly, exenatide appears to be the only GLP1-RA that induces a mild weight loss.

Anti-diabetic drugs and weight loss in patients with type 2 diabetes / E. Lazzaroni, M. Ben Nasr, C. Loretelli, I. Pastore, L. Plebani, M.E. Lunati, L. Vallone, A.M. Bolla, A. Rossi, L. Montefusco, E. Ippolito, C. Berra, F. D'Addio, G.V. Zuccotti, P. Fiorina. - In: PHARMACOLOGICAL RESEARCH. - ISSN 1043-6618. - 171(2021 Sep), pp. 105782.1-105782.9. [10.1016/j.phrs.2021.105782]

Anti-diabetic drugs and weight loss in patients with type 2 diabetes

E. Lazzaroni;M. Ben Nasr;C. Loretelli;M.E. Lunati;L. Vallone;L. Montefusco;E. Ippolito;F. D'Addio;G.V. Zuccotti;P. Fiorina
2021-09

Abstract

Introduction: Obesity is frequently a comorbidity of type 2 diabetes. Even modest weight loss can significantly improve glucose homeostasis and lessen cardiometabolic risk factors in patients with type 2 diabetes, but life-style-based weight loss strategies are not long-term effective. There is an increasing need to consider pharma-cological approaches to assist weight loss in the so called diabesity syndrome. Aim of this review is to analyze the weight-loss effect of non-insulin glucose lowering drugs in patients with type 2 diabetes. Material and methods: A systematic analysis of the literature on the effect of non-insulin glucose lowering drugs on weight loss in patients with type 2 diabetes was performed. For each class of drugs, the following parameters were analyzed: kilograms lost on average, effect on body mass index and body composition. Results: Our results suggested that anti-diabetic drugs can be stratified into 3 groups based on their efficacy in weight loss: metformin, acarbose, empagliflozin and exenatide resulted in a in a mild weight loss (less than 3.2% of initial weight); canagliflozin, ertugliflozin, dapagliflozin and dulaglutide induces a moderate weight loss (between 3.2% and 5%); liraglutide, semaglutide and tirzepatide resulted in a strong weight loss (greater than 5%). Conclusions: This study shows that new anti-diabetic drugs, particularly GLP1-RA and Tirzepatide, are the most effective in inducing weight loss in patients with type 2 diabetes. Interestingly, exenatide appears to be the only GLP1-RA that induces a mild weight loss.
anti-diabetic drugs; body composition; diabesity; type 2 diabetes; weight loss
Settore MED/13 - Endocrinologia
Settore MED/50 - Scienze Tecniche Mediche Applicate
Settore MED/49 - Scienze Tecniche Dietetiche Applicate
22-lug-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
Anti-diabetic drugs and weight loss in patients withtype 2 diabetes.pdf

embargo fino al 22/09/2022

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 1.02 MB
Formato Adobe PDF
1.02 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
1-s2.0-S1043661821003662-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.68 MB
Formato Adobe PDF
1.68 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/860342
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 10
social impact